Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - Frequency and outcomes

Bone Marrow Transplantation

Volumn 33, Issue 7, 2004, Pages 729-734

  Lee, K H ^a   Lee, J H ^a   Choi, S J ^a   Kim, S ^a   Seol, M ^a   Lee, Y S ^a   Kim, W K ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Allogeneic hematopoietic transplantation bone marrow reconstitution; Trilineage reconstitution failure

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FLUDARABINE PHOSPHATE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL LINEAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEATH; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ERYTHROCYTE TRANSFUSION; EXPERIENCE; FEMALE; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOMES RESEARCH; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD CELLS; CELL LINEAGE; CHI-SQUARE DISTRIBUTION; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PANCYTOPENIA; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 16544395817     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704428     Document Type: Article

References (19)

1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517-531.
2. Dubovsky J, Daxberger H, Fritsch G et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060-2069.
3. Nemunaitis J, Singer JW, Buckner CD et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245-253.
4. Grandage VL, Cornish JM, Pamphilon DH et al. Second allogeneic bone marrow transplantation from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation. Bone Marrow Transplant 1998; 21: 687-690.
5. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
6. Champlin RE, Horowitz MM, van Bekkum DW et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606-613.
7. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.
8. Lee J-H, Lee K-H, Kim S et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883-888.
9. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Ann Rev Med 1984; 35: 11-24.
10. Wang F-Z, Dahl H, Linde A et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88: 3615-3620.
11. Lee J-H, Lee J-H, Choi SJ et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Hematol 2003; 120: 702-710.
12. Lee J-H, Lee K-H, Lee J-H et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087-1094.
13. Lee K-H, Lee J-H, Lee J-H et al. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation. Haematologica 2001; 86: 999-1001.
14. Przepiorka D, Weisdorf D, Martin P et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
15. Sullivan K. Acute and chronic graft-versus-host disease in man. Int J Cell Clon 1986; 4: 42-93.
16. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
17. Lee K-H, Lee J-H, Choi S-J et al. Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2003; 32: 423-431.
18. Bacigalupo A, Hows J, Gluckman E et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70: 177-182.
19. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 2000; 37: 56-68.